Under the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10699060		
Filing Date		2003-10-31		
First Named Inventor	Edwa	ard Durell Benjamin		
Art Unit		3745		
Examiner Name Verde		er, Christopher M.		
Attorney Docket Numb	ner .	138766		

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Li int Passage s Appear		
	1	5800124		1998-09-01	Zelesky (US fa EP0801208A2	amily member of 2)				
	2	6196799		2001-03-06	Fukue et al (U JP11236805)	S family member of				
	3	6120249		2000-09-19	Hultgren et al.					
	4	6086329		2000-07-11	Tomita et al.					
If you wisl	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the	Add button.		Add		_
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Li int Passage s Appear		
	1									
If you wisi	h to a	d additional U.S. Publi:	shed Ap	plication citatio	n information p	please click the Ad	d button	Add		_
				FOREIGN PAT	TENT DOCUM	IENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited	e or V	Pages,Colui where Relev Passages or figures App	/ant r Relevant	TS

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

ED000120042

l-p

Application Number		10699060		
Filing Date		2003-10-31		
First Named Inventor	Edward Durell Benjamin			
Art Unit		3745		
Examiner Name Verde		er, Christopher M.		
Attorney Docket Number		138766		

United Technologies

							Corporation		_
	2	JP10	63605A	JP		2007-05-09			
	3	JP11	236805	JP		1998-08-31			
If you wis	h to a	dd add	ditional Foreign P	atent Document	citation	information pl	ease click the Add buttor	n Add	
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Ţ5	
1 CN App. No. 200410088035.1 First Office Action (06 APRIL 2007)									
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a									

1 See Kind Codes of USPTO Planto Documents at year, <u>USPTO CODE</u> or MEPP 901.04. * Enter office that issued the document, by the two-lefter code (WIPO Standard ST3.). * For Ligamente plant occuments, the reduction of the year of the reign of the Engineer contraction code the sellar instruction of the plant document.

**Incl of Cocument by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if gouether. * Applicant is to place a check mark here if Engine Integrage instructions in attacked.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10699060
Filing Date		2003-10-31
First Named Inventor Edwa		rd Durell Benjamin
Art Unit		3745
Examiner Name Verde		er, Christopher M.
Attorney Docket Number		138766

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

	That no item of information contained in the information disclosure statement was cited in a communication from a
	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
	after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
_	any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
	statement. See 37 CFR 1.97(e)(2).

٦.	See	attached	certification	etatement

٦	Fee set forth in 37	CFR 1 17 (r) has been	submitted herewith.

_ N--

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/s/ Robert B. Reeser, III	Date (YYYY-MM-DD)	2007-05-09
Name/Print	Robert B. Reeser, III	Registration Number	45,548

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.